Palatin Technologies, Inc.
Palatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
Advancing differentiated next-generation MC4R agonists toward first-in-human clinical studies in 2027 Lead lipidated, long-acting MC4R-selective…
